Device-detected atrial fibrillation: what to do with asymptomatic patients?

Carol Chen-Scarabelli1, Tiziano M Scarabelli2, Kenneth A Ellenbogen3

  • 1Veterans Affairs Ann Arbor Health Care System, University of Michigan, Ann Arbor, Michigan.

Insights

Subclinical atrial tachyarrhythmias (ATs) detected by devices increase stroke risk. Guidelines recommend stroke risk assessment and anticoagulation for nonvalvular atrial fibrillation (AF) to prevent thromboembolic events.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Neurology

Background:

  • Atrial fibrillation (AF) is a prevalent arrhythmia associated with significant stroke risk.
  • Subclinical atrial tachyarrhythmias (ATs) detected by cardiac implantable electronic devices (CIEDs) are linked to thromboembolic events.
  • Clinical management of device-detected AT often involves delayed treatment or continued surveillance.

Purpose of the Study:

  • To review the epidemiology of atrial fibrillation.
  • To discuss the mechanisms of stroke in patients with AF.
  • To examine the clinical implications of device-detected AF and its association with stroke risk.

Main Methods:

  • Literature review of epidemiological data on AF.
  • Analysis of mechanisms linking AF to thromboembolic events.
  • Discussion of current clinical practice guidelines and device-detected AF management.

Main Results:

  • AF increases stroke risk irrespective of symptoms.
  • Device-detected ATs are associated with a higher risk of thromboembolic events.
  • Current guidelines recommend stroke risk stratification using CHA2DS2-VASc score for nonvalvular AF.

Conclusions:

  • Oral anticoagulation is recommended for nonvalvular AF with CHA2DS2-VASc score ≥2.
  • Device-detected AF warrants careful consideration for stroke prevention strategies.
  • Further research and updated clinical approaches are needed for managing device-detected ATs.

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
640
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.1K
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
5.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
642
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
488
Dysrhythmias V: Evaluating Dysrhythmias01:30

Dysrhythmias V: Evaluating Dysrhythmias

Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
489